Brief: Hyloris Reports Positive Phase 1 Data For HY-004

Hyloris Pharmaceuticals SA

20/07/2022 06:08

July 20 (Reuters) - Hyloris Pharmaceuticals SA  HYL.BR :
    * HYLORIS REPORTS POSITIVE PHASE 1 DATA FOR HY-004, A
PROPRIETARY
TRANEXAMIC ACID ORAL MOUTH RINSE FOR BLEEDING RELATED TO DENTAL
PROCEDURES
    * HY-004 PROVIDES A NEW TREATMENT ALTERNATIVE FOR USE IN
PATIENTS
ON ANTI-COAGULANT THERAPIES UNDERGOING DENTAL PROCEDURES THAT
HAVE A RISK OF BLEEDING OR COMPLICATION
    * HY-004 ADMINISTERED LOCALLY HAD MINIMAL SYSTEMIC EXPOSURE
AND
WAS WELL-TOLERATED FOLLOWING MOLAR EXTRACTION IN HEALTHY
PATIENTS
    * HY-004 TO BE DEVELOPED TO ADDRESS A SIGNIFICANTLY LARGER
TARGET
MARKET
    * PIVOTAL STUDY EXPECTED TO START EARLY NEXT YEAR TO USHER
HY-004
INTO LATER STAGE DEVELOPMENT

Source text for Eikon:  ID:nGNE71PMrg 
Further company coverage:  HYL.BR 

 (Gdansk Newsroom)
 ((Gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))